NEWARK, Calif., Sept. 3, 2019 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
Executive Officer, will provide a corporate overview at the H.C.
Wainwright & Co. 2019 Annual Healthcare Conference in
New York.
Presentation
details:
Event: H.C. Wainwright & Co.
2019 Annual Healthcare Conference
Date: Tuesday, September 10, 2019
Time: 9:10 a.m. EDT
A live and archived webcast of the presentation can be accessed
by visiting the Investors page of the Protagonist Therapeutics
website at http://investors.protagonist-inc.com.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to transform existing
treatment paradigms for patients with significant unmet medical
needs. PTG-300 is an injectable hepcidin mimetic in development for
the treatment of iron overload anemia and related rare blood
diseases. PTG-300 is currently in a global Phase 2 study in
beta-thalassemia. PTG-200 is an oral, gut-restricted interleukin-23
receptor specific antagonist peptide in clinical development for
the potential treatment of inflammatory bowel disease. The Company
has a worldwide license and collaboration agreement with Janssen
Biotech for the clinical development of PTG-200 and a Phase 2 study
in Crohn's disease is expected in fourth quarter of 2019. PN-943 is
an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist
peptide in clinical development for the potential treatment of
inflammatory bowel disease, with ulcerative colitis as the initial
intended indication.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-hc-wainwright--co-2019-annual-healthcare-conference-300910803.html
SOURCE Protagonist Therapeutics, Inc.